<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors -Results from the PAN Study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-07-28">July 28, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Jona</forename><forename type="middle">T</forename><surname>Stahmeyer</surname></persName>
							<email>stahmeyer.jona@mh-hannover.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Institute for Epidemiology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">Social Medicine and Health Systems Research</orgName>
								<address>
									<settlement>Hannover, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Siegbert</forename><surname>Rossol</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Krankenhaus Nordwest</orgName>
								<address>
									<settlement>Frankfurt a.M., Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><surname>Bert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><forename type="middle">H W</forename><surname>Böker</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Krankenhaus Nordwest</orgName>
								<address>
									<settlement>Frankfurt a.M., Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<address>
									<settlement>Leberpraxis, Hannover, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harald- Robert</forename><surname>Bruch</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Schwerpunktpraxis Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Eisenbach</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Dept. of Gastroenterology</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Heidelberg, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ralph</forename><surname>Link</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">St. Josefs Hospital</orgName>
								<address>
									<settlement>Offenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>John</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Medical Practice</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Mauss</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Center for HIV and Hepatogastroenterology</orgName>
								<address>
									<settlement>Duesseldorf</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Heyne</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Leberzentrum am Checkpoint</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eckart</forename><surname>Schott</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Dept. of Hepatology and Gastroenterology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, 11 e-factum -GmbH</addrLine>
									<settlement>Berlin, Germany, Butzbach, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Heike</forename><surname>Pfeiffer-Vornkahl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dietrich</forename><surname>Hüppe</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Center of Gastroenterology</orgName>
								<address>
									<settlement>Herne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Krauth</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Institute for Epidemiology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">Social Medicine and Health Systems Research</orgName>
								<address>
									<settlement>Hannover, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gmbh</forename><surname>Deutschland</surname></persName>
						</author>
						<author>
							<persName><forename type="first">)</forename><surname>Carl-Neuberg-Straße</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Institute for Epidemiology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<orgName type="institution">Social Medicine and Health Systems Research</orgName>
								<address>
									<settlement>Hannover, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hannover</forename><surname>Germany</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Co</forename><surname>Kg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Bristol-Myers</forename><surname>Squibb</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gmbh</forename><surname>Co</surname></persName>
						</author>
						<author>
							<persName><surname>Kgaa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sciences</forename><surname>Gilead</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Janssen-Cilag</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><roleName>MSD</roleName><forename type="first">Sharp</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dohme</forename><surname>Gmbh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Roche</forename><surname>Pharma</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>The</surname></persName>
						</author>
						<author>
							<persName><forename type="first">German</forename><surname>Liver</surname></persName>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">University of North Carolina School of Medicine</orgName>
								<orgName type="institution" key="instit2">UNITED STATES</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors -Results from the PAN Study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-07-28">July 28, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">E47D2530D32807B98EA6C2C664C080BD</idno>
					<idno type="DOI">10.1371/journal.pone.0159976</idno>
					<note type="submission">Received: May 19, 2016 Accepted: July 11, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Objective</head><p><s>Chronic hepatitis C virus infections (HCV) cause a significant public health burden.</s><s>Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects.</s><s>Aim of the study was to assess outcomes and costs of treating HCV with TVR or BOC in routine care.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Material and Methods</head><p><s>Data was obtained from a non-interventional study.</s><s>This analysis relates on a subset of 1,786 patients for whom resource utilisation was documented.</s><s>Sociodemografic and clinical parameters as well as resource utilisation were collected using a web-based data recording system.</s><s>Costs were calculated using official remuneration schemes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head><p><s>Mean age of patients was 49.2 years, 58.6% were male.</s><s>In treatment-naive patients SVRrates of 62.2% and 55.7% for TVR and BOC were observed (prior relapser: 68.5% for TVR and 63.5% for BOC; prior non-responder: 45.6% for TVR and 39.1% for BOC).</s><s>Treatment costs are dominated by costs for pharmaceuticals and range between €39,081 and PLOS ONE |</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Chronic hepatitis C virus infections (HCV) cause a significant public health burden.</s><s>Worldwide, about 170 million people are chronically infected with HCV <ref type="bibr" target="#b0">[1]</ref>.</s><s>Data from the German National Health and Examination Survey (DEGS1) estimate an anti HCV-prevalence of 0.3% in the general population <ref type="bibr" target="#b1">[2]</ref>.</s><s>More extended studies which consider a higher prevalence in risk-groups such as drug abusers, prison inmates and some urban areas, estimated the number of patients with a viremic infection at 275,000 (165,000-494,000) in Germany <ref type="bibr">[3;4]</ref>.</s><s>The majority of patients have acquired genotype 1 or 3 hepatitis C virus <ref type="bibr" target="#b5">[5]</ref>.</s><s>A large part of infected patients are unaware of their disease.</s><s>Most infections remain undiagnosed until serious and potentially lethal complications such as liver cirrhosis and hepatocellular carcinoma occur <ref type="bibr" target="#b7">[6]</ref>.</s></p><p><s>Estimates assume that about 27% of liver cirrhosis and 25% of hepatocellular carcinoma (HCC) are attributable to chronic HCV <ref type="bibr" target="#b8">[7]</ref>.</s><s>Further, chronic hepatitis C is still the most common cause for liver transplantations <ref type="bibr" target="#b9">[8]</ref>.</s><s>The primary goal of treating hepatitis C is to eradicate the virus (sustained viral response, SVR) and thus to reduce the morbidity and mortality of infected patients.</s><s>Recent studies have shown that SVR is associated with a decreasing risk of liver cirrhosis, liver-related mortality and all-cause mortality as well as an increase in quality of life <ref type="bibr" target="#b10">[9]</ref><ref type="bibr" target="#b11">[10]</ref><ref type="bibr" target="#b12">[11]</ref>.</s></p><p><s>The introduction of first generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) for the treatment of patients infected with HCV genotype 1 in 2011 has significantly increased SVR rates while shortening treatment duration for many patients.</s><s>Especially treatment-experienced patients who failed to previous treatment attempts with peginterferon (PegIFN) and ribavirin (RBV) dual therapy have benefited from these treatment options.</s><s>In 2012, the Joint Federal Committee (Gemeinsamer Bundesausschuss) estimated the number of patients eligible for treatment at 46,000 in Germany (treatment-naive: 12,000; treatment-experienced 34,000) <ref type="bibr">[12;13]</ref>.</s><s>From 2011 to 2014, triple therapy with TVR or BOC has been established as the new standard of care <ref type="bibr" target="#b15">[14]</ref>.</s><s>However, triple-therapy with first generation protease inhibitors is associated with significantly increased adverse events and patients with advanced fibrosis or other comorbidities are often not eligible for treatment <ref type="bibr" target="#b16">[15]</ref>.</s><s>Further, treatment options are associated with increased costs.</s><s>Although several cost-effectiveness studies have shown that treatment with TVR or BOC is cost-effective, there is still a lack of studies evaluating outcomes and costs of treating hepatitis C with TVR and BOC in a real-life setting.</s></p><p><s>A study by <ref type="bibr" target="#b17">Bichoupan et al. (2014)</ref> showed extremely high costs of $189,000 per SVR for patients receiving first generation protease inhibitors <ref type="bibr" target="#b17">[16]</ref>.</s><s>In another real-life study average SVR-rates of 53% for TVR and 40% for BOC were observed <ref type="bibr" target="#b18">[17]</ref>.</s><s>Due to small sample sizes, extensive subgroup analyses could not be conducted and generalisation of these results is doubtful.</s><s>First interim data from the "Peginterferon alfa-2a non-interventional trial" (PAN) cohort showed SVR-rates in treatment-naive patients of 63.4% and 55.0% for TVR and BOC, respectively.</s><s>Results were lower in treatment-experienced patients, except for patients with prior relapse <ref type="bibr" target="#b19">[18]</ref>.</s></p><p><s>Therefore, the aim of this study was to analyse outcomes and healthcare costs of treating patients with TVR or BOC in routine care using the largest cohort of HCV infected patients so far.</s><s>Further, information on quality of life was collected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>The data analyzed are part of the PAN trial.</s><s>The PAN study is a prospective, open-label, multicenter, non-interventional study started in 2011 and initiated by the Association of German Gastroenterologists in Private Practice (Berufsverband Niedergelassener Gastroenterologen Deutschlands e.V.) in cooperation with Roche Pharma AG, Germany.</s><s>It is a continuation of a non-interventional study analyzing effectiveness and treatment costs of patients receiving peginterferon and ribavirin <ref type="bibr" target="#b20">[19]</ref><ref type="bibr" target="#b21">[20]</ref><ref type="bibr" target="#b22">[21]</ref>.</s><s>The design of the study was approved by the Ethical Committee of the Aerztekammer Westfalen-Lippe and patients gave written informed consent before taking part in the study.</s><s>Inclusion criteria were indication for therapy of chronic hepatitis C according to the attending physician as well as an age of 18 years or above.</s><s>Federal health authorities were infomed about the study: The trial was registered at the Association of Researching Pharmaceutical Manufacturers (ML25724) and at ClinicalTrials.gov</s><s>(NCT01679834).</s><s>Sponsor according to GCP/GEP of the non-interventional study was Roche Pharma AG, Germany.</s><s>The authors were independent from the funding institutions in data analysis, data interpretation, report writing and publication.</s></p><p><s>A web-based data recording system was used for data collection.</s><s>The quality of the data was assessed by automated plausibility checks as well as additional on-site monitoring.</s><s>Data collection included treatment outcomes (SVR), sociodemographic and clinical parameters, HCVassociated health care utilisation and quality of life (QoL).</s><s>SVR was defined as undetectable HCV RNA at least 10 weeks after end of treatment (EoT).</s><s>This definition was used because timing of patient visits was not specified and thus some patients may not have had a physician visit at exactly 12 or 24 weeks after end of treatment.</s><s>Accordingly, patients without HCV RNA determination 10 weeks or later after EoT or patients who were lost to follow-up were considered to have failed treatment in our analysis (intention-to-treat analysis).</s></p><p><s>Healthcare utilisation comprises outpatient care (doctor visits, laboratory testing and imaging), pharmaceuticals (antiviral treatment and medication for the treatment of HCV-associated diseases or treatment-related adverse events) as well as HCV-associated hospitalisation.</s><s>Costs of outpatient care and services are based on the German doctors' fee scale within the statutory health insurance scheme (Einheitlicher Bewertungsmaßstab), pharmaceutical costs were calculated using prices from the German drug directory (Rote-Liste) and hospital costs were calculated based on the German hospital reimbursement scheme (G-DRG) <ref type="bibr" target="#b23">[22]</ref><ref type="bibr" target="#b24">[23]</ref><ref type="bibr">[24]</ref>.</s><s>Price year was 2012.</s></p><p><s>Information on QoL was collected using the German version and transformation of the Short-Form-36 version 2 (SF-36v2).</s><s>Patients were asked to fill out the questionnaires at four different times of treatment: (1.) baseline, (2.) treatment week 12, (3.) end of treatment, (4.) 10 to 24 weeks post treatment (SVR evaluation).</s></p><p><s>The present analysis is based on data from a defined subset of HCV-patients receiving antiviral treatment with TVR or BOC in combination with PegIFN and RBV and for whom detailed information on resource utilisation was documented.</s><s>Patients with HIV co-infection and/or patients reveiving drug substitution treatment were excluded.</s><s>Treatment was recommended to be in accordance with the drug safety: SmPC (summary of product characteristics) and national treatment guidelines but was ultimately at the discretion of the physician in charge.</s><s>In total, data on 1,786 genotype 1 patients were analysed.</s><s>Data were gathered between June 2011 and January 2014 and provided by 191 participating centers (160 outpatient practices and medical centers as well as 31 hospital-based outpatient clinics) all throughout Germany and thus reflects the accepted practice of HCV-treatment in Germany.</s></p><p><s>Statistical analyses are primarily descriptive to reflect the non-interventional character of the study.</s><s>We used SPSS Statistics 12 for the analyses.</s><s>Differences between subgroups were analysed using the T-Test or χ²-Test depending in type of variable.</s><s>Differences were regarded as significant at a level of p0.05.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Characteristics</head><p><s>Overall, data on 1,786 patients receiving triple-therapy with BOC (25.3%) or TVR (74.7%) were analysed.</s><s>Mean age was 49.2 years (SD 11.2), 58.6% were male.</s><s>Mean height and weight were 172.3 cm (SD 9.4) and 79.2 kg (SD 15.3), respectively (Body-Mass-Index 26.6; SD 4.5).</s><s>Almost all patients were Caucasian.</s><s>Estimated duration of infection was 16.9 years (SD 10.9) on average.</s><s>Most common routes of transmission were historical intravenous drug abuse (19.4%), blood products (17.4%) and surgical/medical interventions (8.5%).</s><s>For almost half of the patients (49.7%) the route of transmission was unknown.</s><s>About half of patients were treatment-naive (44.5%), 29.8% had a relapse and 22.6% had non-response to previous therapy with PegIFN/RBV.</s><s>Other patients (2.8%) discontinued previous treatment due to adverse events and/or personal reasons and six patients (0.3%) had a reinfection.</s><s>Comorbidities were frequent in our sample (58.9%).</s><s>Most frequent diseases were cardiovascular diseases (20.5%), psychiatric disorders (12.4%), thyroidal dysfunction (9.1%) and diabetes mellitus (7.8%).</s><s>15 patients (0.8%) were co-infected with hepatitis B virus.</s><s>A history of alcohol and/or drug abuse was observed for 18.4% of patients.</s></p><p><s>Baseline viral load was available for 1,742 patients (97.5%).</s><s>Average viral load was 3.01 million IU; 27.2% of patients had a low viral load (400,000 IU/ml) and 72.8% had a high viral load (&gt;400,000 IU/ml).</s><s>Mean levels of AST and ALT were 67.7 U/I and 92.7 U/I, respectively.</s></p><p><s>Due to the non-interventional character of the study, no standardized evaluation on liver fibrosis was performed.</s><s>Information on liver fibrosis/cirrhosis was gathered by available information.</s><s>Most patients (79.9%) received at least one ultrasound examination of the liver; 15.8% had a liver biopsy.</s><s>Information on other methods for evaluation of liver fibrosis (e.g.</s><s>FibroScan, FibroTest or acoustic radiation force impulse) was not sufficiently documented.</s><s>Further, these methods are not covered by the statutory health insurance and have to be paid by the patients themselves.</s><s>Based on available data (e.g.</s><s>biopsy, clinical appearance, sonography, elastography) 14.2% of patients were classified as cirrhotics.</s><s>We further used APRI-score to determine the degree of liver fibrosis/cirrhosis.</s><s>Mean APRI-score was 1.0 (SD 1.32; n = 1,483).</s><s>An APRIscore of 0.5 indicating no significant fibrosis was observed in 42.9% of patients, 39.8% had a score &gt;0.5 and 1.5 and 17.3% had a score &gt;1.5 indicating advanced fibrosis or liver cirrhosis.</s><s>Patient characteristics are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment response</head><p><s>Overall, we observed an SVR-rate of 58.2% in our total sample who received treatment with either TVR or BOC (n = 1,786).</s><s>In treatment-naive patients SVR-rates of 62.2% and 55.7% were observed for TVR and BOC, respectively.</s><s>Difference between TVR and BOC treatment was not significant (p = 0.085, mean difference 6.5%, 95%-CI -0.9-14.0).</s><s>SVR-rates in patients with relapse to previous treatment were 68.5% in patients receiving TVR and 63.5% in patients receiving BOC (p = 0.35, mean difference 5.0%, 95%-CI -5.3-15.4).</s><s>In patients with nonresponse to previous treatment SVR-rates were 45.6% in TVR and 39.1% in BOC (p = 0.33, mean difference 6.5%, 95%-CI -5.3-18.3).</s></p><p><s>In total, 476 of 1,786 patients (26.7%) discontinued treatment with BOC or TVR.</s><s>Reasons for treatment discontinuation were insufficient virologic response, adverse events or other non-medical reasons.</s><s>Average treatment duration in treatment-naive patients was 27.2 weeks in TVR and 31.7 weeks in BOC.</s><s>49.8% of treatment-naive patients received TVR for about 24 weeks and 18.8% for about 48 weeks.</s><s>In patients receiving BOC 52.0% received treatment for about 28 weeks and 24.0% for 48 weeks.</s><s>In treatment-experienced patients treatment durations were 31.6 weeks (38.5% received treatment for about 24 weeks and 35.7% for about 48 weeks) and 41.2 weeks (11.5% received treatment for about 28 weeks and 70.2% for about 48 weeks) in patients with prior relapse and 33.0 weeks (11.4% received treatment for about 24 weeks and 45.8% for about 48 weeks) and 34.7 weeks (10.3% received treatment for about 28 weeks and 51.7% for about 48 weeks) in patients with prior non-response for TVR and BOC, respectively.</s><s>Information on response rates and treatment duration are summarized in Table <ref type="table" target="#tab_1">2</ref>. Shorter treatment duration in BOC patients with prior non-response compared to prior relapsers is due to more frequent treatment discontinuations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse events</head><p><s>Adverse events (AE) were common in patients receiving TVR or BOC treatment.</s><s>90.5% of patients had at least one non-serious AE.</s><s>Most common non-serious AEs were fatigue (62.9%), skin diseases (35.9%), pruritus (31.2%), nausea (25.8%), anemia (25.6%), headache (22.3%), arthralgia (17.7%), sleeplessness (16.2%), depressive mood (14.4%) and fever (13.4%).</s></p><p><s>Serious adverse events were observed in 11.2% of treated patients.</s><s>Most frequent SAEs were anemia (42 patients; 2.4%), rash (14 patients; 0.8%), pancytopenia (10 patients; 0.6%), fever (7 patients, 0.4%) and sepsis (7 patients, 0.4%).</s><s>4.3%% (TVR) and 0.9% (BOC) of patients discontinued therapy due to adverse events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Resource utilisation and costs</head><p><s>On average, patients had 12.1 doctor visits.</s><s>However, patients receiving treatment with TVR had less doctor visits compared to BOC patients (11.7 vs. 13.3;</s><s>p&lt;0.0001).</s><s>Besides antiviral treatment with either TVR or BOC, nearly all patients (93.5%) received co-medication for the treatment of HCV-associated diseases or therapy related side effects.</s><s>100 patients (5.6%) needed to be treated as inpatients due to their HCV-infection or therapy related side effects.</s><s>Average length of inpatient care was 4.8 days.</s><s>Calculation of treatment costs is based on 1,784 patients as complete resource utilisation data were not available for two patients (one TVR and one BOC).</s><s>The costs for ambulatory care amount for €1,098 on average (TVR: €1,071; BOC: €1,179).</s><s>These include costs for doctor visits, laboratory services and imaging techniques which are necessary for initiating antiviral treatment as well as treatment monitoring.</s><s>Average pharmaceutical costs were €48,562 and contain antiviral treatment with TVR or BOC with PegIFN and RBV (€48,549) and costs for co-medication (€13).</s><s>Antiviral treatment costs were higher in patients receiving triple-therapy with TVR (€50,862) compared to BOC patients (€41,693).</s><s>Average costs for co-medication were almost identical (TVR: €13; BOC: €14).</s><s>Mean costs for inpatient care were €165 for the total population (TVR: €188; BOC: €99).</s><s>Average costs in 100 patients who were treated as inpatients were €2,946 (TVR: €2,979; BOC: €2,778).</s><s>Total treatment costs sum up for €49,826 (TVR: €52,120; BOC: €42,970).</s><s>Further, costs were stratified by treatment status (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Costs per SVR</head><p><s>Based on SVR-rates and cost estimates in different patient groups we determined how much money has to be spent to achieve SVR in one person with HCV.</s><s>In treatment-naive patients average costs were 81,347 €/SVR for patients receiving TVR and 70,163 €/SVR for patients treated with BOC.</s><s>Average costs per SVR in patients with relapse to prior treatment were €78,089 and €82,077 for TVR and BOC, respectively.</s><s>In patients with non-response to previous treatment average costs were 116,509 €/SVR (TVR) and 110,156 €/SVR (BOC).</s><s>Costs per SVR estimates are summarized in Table <ref type="table" target="#tab_3">4</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality of life</head><p><s>Complete information on quality of life was not available for the total study population as some patients did not fill out the questionnaires at all or did not fill out questionnaires regularly.</s><s>Therefore, we used three different sub-samples to conduct quality of life analyses and to use all patients available:</s></p><p><s>1. Quality of life of infected patients (baseline analysis)</s></p><p><s>2. Development of quality of life during treatment (complete data analysis)</s></p><p><s>3. Differences in quality of life depending on SVR (10 weeks or later post treatment analysis)</s></p><p><s>Complete data on QoL at baseline were available for 422 patients.</s><s>The analysis supports the evidence that chronic HCV infection is associated with reduced QoL compared to QoL in the general population.</s><s>Biggest QoL restrictions were observed for general health (-19%), vitality (-19%) and role-emotional (-15%).</s><s>All SF-36 QoL subscales showed significantly lower values, except for bodily pain.</s><s>Further, QoL sumscores were significantly lower compared to general population (Table <ref type="table" target="#tab_4">5</ref>).</s></p><p><s>To analyse the reduction as well as the development of quality of life during antiviral treatment all patients who participated in all surveys (baseline, treatment week 12, end of treatment, 24 weeks post treatment) were analyzed (n = 316).</s><s>The analysis shows a significant decrease in quality of life during treatment (baseline vs. treatment week 12) for all SF-36 scales, whereas decrease is greatest in role-physical (-52.0%),</s><s>vitality (-43.6%) and role-emotional (-40.5%).</s><s>Development of quality of life is described in Fig 1 <ref type="figure">.</ref></s><s>At the end of treatment QoL increases.</s><s>Detailed information on QoL stratified for TVR and BOC is presented in the appendix.</s><s>Post treatment QoL scales show higher or equal values compared to baseline.</s><s>A comparison of patients who achieved SVR and patients who failed treatment demonstrates that achievement of SVR is associated with an increased QoL.</s><s>All SF-36 subscales, except role-physical and bodily pain, show higher values (Table <ref type="table" target="#tab_5">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>We evaluated outcomes and costs of treating genotype 1 patients with first generation protease inhibitors TVR and BOC in a real-life setting using data from the German Hepatitis C Registry.</s><s>Data on 1,786 patients was provided by 191 outpatient practices and hospital outpatient departments throughout Germany using a web-based data recording system.</s><s>To our knowledge, this is the largest real-life cohort of patients receiving first generation protease inhibitors TVR or BOC so far.</s></p><p><s>We observed SVR-rates of 62.2% for TVR and 55.7% for BOC in treatment-naive patients and thus confirm results from an interim analysis with a smaller patient sample <ref type="bibr" target="#b19">[18]</ref>.</s><s>These rates are considerably lower than rates observed in clinical trials (TVR: 75%; BOC: 66%) <ref type="bibr">[25;26]</ref>.</s><s>Similar results were shown for treatment-experienced patients <ref type="bibr">[27;28]</ref>.</s><s>In total, 153 patients (8.6%) were lost to follow-up or not tested.</s><s>These findings are frequently observed as clinical trial populations usually do not reflect the population treated in routine care.</s><s>Furthermore, treatment monitoring is more frequent and compliance is encouraged more intensely and treatment discontinuations are less frequent due to strict study protocols.</s><s>Therefore, higher rates of lost to follow-up patients are not unusual in real-life settings.</s></p><p><s>Another US study by <ref type="bibr" target="#b29">Backus et al. (2014)</ref> evaluated outcomes of TVR and BOC treatment in a cohort of HCV-infected veterans.</s><s>SVR-rates did not significantly differ between both treatments in the total cohort (TVR: 52%, BOC: 50%, p = 0.72) as well as subgroups.</s><s>Outcome in treatment-naive patients were 55% and 53% for TVR and BOC, respectively.</s><s>Lower SVR-rates were observed for treatment-experienced patients, except for patients with prior relapse.</s><s>Further, patients with cirrhosis were less likely to achieve SVR <ref type="bibr" target="#b29">[29]</ref>.</s></p><p><s>Two other studies by <ref type="bibr" target="#b18">Vo et al. (2015)</ref> and <ref type="bibr" target="#b30">Wehmeyer et al. (2014)</ref> confirm these results and prove that results from clinical trials could not be easily reproduced in routine care <ref type="bibr">[17;30]</ref>.</s><s>Vo et al. showed SVR-rates of 53% for TVR and 40% for BOC.</s><s><ref type="bibr" target="#b18">[17]</ref> Wehmeyer et al. observed a SVR-rate of 60.8% whereas no significant differences between TVR and BOC were observed <ref type="bibr" target="#b30">[30]</ref>.</s><s>Both analyses confirm lower SVR-rates in patients with cirrhosis.</s></p><p><s>In treatment-naive patients average treatment costs of €50,598 for TVR and €39,081 for BOC were observed.</s><s>In treatment-experienced patients average treatment costs were slightly higher.</s><s>We estimated average costs per SVR of €81,347 for TVR and €70,163 for BOC in treatment-naive patients.</s><s>In treatment-experienced patients costs per SVR were about €80,000 in prior relapse for both TVR and BOC.</s><s>In prior non-responder costs were 116,509 €/SVR and 110,156 €/SVR for TVR and BOC, respectively.</s></p><p><s>A study by <ref type="bibr" target="#b17">Bichoupan et al. (2014)</ref> showed median treatment costs per SVR of $189,338 for patients receiving antiviral treatment with TVR in the United States <ref type="bibr" target="#b17">[16]</ref>.</s><s>These data should be interpreted with caution as 35% of patients had advanced fibrosis/cirrhosis and 73% had received dual therapy with PegIFN and RBV in the past.</s><s>Median treatment costs were $83,721 and only 44% of patients achieved SVR.</s><s>Subgroup analyses showed higher costs and lower SVR rates in treatment-experienced patients and patients with advanced fibrosis/cirrhosis <ref type="bibr" target="#b17">[16]</ref>.</s></p><p><s>Compared to real-life treatment outcomes and costs in genotype 1 patients receiving dual therapy with PegIFN and RBV, our analysis shows higher costs per SVR.</s><s><ref type="bibr" target="#b20">[19]</ref> Average costs per SVR in dual treatment were €44,744 in treatment-naive patients, €73,816 in patients with prior relapse and €81,796 in patients with prior non-response.</s><s>Furthermore, the decrease of QoL during treatment was greater in patients receiving TVR or BOC compared to dual treatment with PegIFN and RBV <ref type="bibr" target="#b20">[19]</ref>.</s></p><p><s>Therefore, this analysis supports the findings from previous studies and demonstrates that triple therapy with TVR or BOC is associated with a significant reduction in QoL mostly due to therapy-related side effects/adverse events.</s><s>Further, we could show that the achievement of SVR is associated with an increase in QoL.</s></p><p><s>Long-term cost effectiveness of TVR and BOC treatment including costs of disease progression in patients who do not achieve SVR in respective treatments have been comprehensively evaluated in different countries (e.g.</s><s>USA, Italy, UK, Germany) <ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref>.</s><s>These analyses show that TVR and BOC could be considered as cost-effective.</s><s>Model results are mainly influenced by the discount rate, SVR-rates and treatment costs <ref type="bibr" target="#b31">[31]</ref><ref type="bibr" target="#b32">[32]</ref><ref type="bibr" target="#b33">[33]</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b36">[36]</ref><ref type="bibr" target="#b37">[37]</ref>.</s></p><p><s>A major limitation of our study is that patients were not randomly assigned to participate.</s><s>Patients were recruited by study centers based on availability and their willingness to participate.</s><s>This could lead to a response bias.</s><s>However, potential bias could be regarded as low due to the large patient sample.</s><s>Although healthcare utilisation was collected timely by filling out standardized form in the web-based recording system, missing data (e.g.</s><s>medical specialist visits) might lead to an underestimation of actual costs.</s><s>As major cost drivers are HCV-medication and HCV-related diagnostics, the impact of missing data is low.</s><s>Results are based on a homogeneous population consisting of Caucasian patients.</s><s>Therefore, transferability of results to other countries may be limited.</s><s>However, the strengths of our study are comprehensive information on patient characteristics, a data quality assurance system and a large patient sample provided by a large number of study centers throughout Germany reflecting routine care in daily practice.</s></p><p><s>Recent developments in treating HCV have increased SVR-rates in all HCV genotypes, shortened treatment duration and lead to a favorable side effect profile.</s><s>These new DAAs allow treating patients with prior contraindication for antiviral treatment due to interferon intolerance, advanced stages of liver disease, older age or comorbidities.</s><s>In treatment-naive genotype 1 patients, treatment with sofosbuvir/ledipasvir (SOF/LDV) with or without RBV or combination treatment with paritaprevir/ritonavir/ombitasvir/dasabuvir (PTV/r/OMV/DSV) with or without RBV results in SVR-rates above 95% <ref type="bibr" target="#b38">[38]</ref><ref type="bibr" target="#b39">[39]</ref><ref type="bibr" target="#b40">[40]</ref><ref type="bibr" target="#b41">[41]</ref><ref type="bibr" target="#b42">[42]</ref>. High SVR-rates were also achieved in treatment-experienced genotype 1 patients as well as in other genotypes <ref type="bibr">[43;44]</ref>.</s><s>These advances in HCV-treatment were accompanied by a further increase in treatment costs and have raised the question, whether such high prices are affordable <ref type="bibr" target="#b45">[45]</ref><ref type="bibr" target="#b46">[46]</ref><ref type="bibr" target="#b47">[47]</ref>.</s><s>For example, weekly costs of new agents are $8,750 for SOF/LDV, $7,000 for SOF, $6,943 for PTV/r/OMV/DSV in the United States.</s><s>Due to high costs several European countries have delayed the introduction of new DAAs and restricted the use for patients with advanced liver disease <ref type="bibr" target="#b48">[48]</ref><ref type="bibr" target="#b49">[49]</ref><ref type="bibr" target="#b50">[50]</ref>.</s><s>Despite high prices, new DAA regimens SOF/LDV and PTV/r/OMV/DSV seem to be cost-effective considering national or international accepted willingness-to-pay thresholds <ref type="bibr" target="#b51">[51]</ref><ref type="bibr" target="#b52">[52]</ref><ref type="bibr" target="#b53">[53]</ref><ref type="bibr" target="#b54">[54]</ref>.</s><s>Due to significant differences in health systems, structures of healthcare provision and costs between countries, transferability of economic evaluation results is limited <ref type="bibr" target="#b55">[55]</ref>.</s><s>Therefore, there is high need for national health economic evaluation results from real-life studies as well as short and long-term modelling studies.</s></p><p><s>Summarizing the results of our study, we estimated average costs of hepatitis C triple-therapy with TVR or BOC therapy in clinical practice ranging between €39,081 in treatment-naive patients receiving BOC and €53,491 in treatment-experienced patients (relapser) receiving TVR.</s><s>Costs per SVR in treatment-naive patients were €81,347 and €70,163 for TVR and BOC, respectively.</s><s>Highest costs per SVR were observed in patients with non-response to prior treatment (TVR: €116,509; BOC €110,156).</s><s>Further, insights on QoL of HCV-infected patients were described.</s><s>Therefore, these data can set a basis for a comparison with newly introduced DAA regimens and help to objectify the current discussion concerning high prices for HCV medication.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="9,200.01,78.01,255.12,576.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient characteristics (n = 1,786, otherwise stated).</s></p></div></figDesc><table><row><cell>Parameter</cell><cell>All patients (n = 1,786)</cell><cell>TVR</cell><cell>BOC</cell><cell>TVR vs. BOC p-value</cell></row><row><cell>Age, years</cell><cell>49.2</cell><cell>49.3</cell><cell>49.0</cell><cell>n.s.</cell></row><row><cell>Sex, %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>male</cell><cell>58.6</cell><cell>60.7</cell><cell>52.1</cell><cell>0.0013</cell></row><row><cell>female</cell><cell>41.4</cell><cell>39.3</cell><cell>47.9</cell><cell></cell></row><row><cell>Height, cm</cell><cell>172.3</cell><cell>172.5</cell><cell>171.7</cell><cell>0.0063</cell></row><row><cell>Weight, kg</cell><cell>79.2</cell><cell>79.0</cell><cell>79.8</cell><cell>n.s.</cell></row><row><cell>Body-Mass-Index</cell><cell>26.6</cell><cell>26.5</cell><cell>27.0</cell><cell>0.0397</cell></row><row><cell>Duration of infection, years</cell><cell>16.9</cell><cell>16.6</cell><cell>17.8</cell><cell>0.0425</cell></row><row><cell>Medical history</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Treatment-naive</cell><cell>44.5</cell><cell>41.0</cell><cell>54.5</cell><cell>&lt;0.001</cell></row><row><cell>Relapser</cell><cell>29.8</cell><cell>32.1</cell><cell>23.1</cell><cell></cell></row><row><cell>Non-responder</cell><cell>22.6</cell><cell>23.7</cell><cell>19.3</cell><cell></cell></row><row><cell>Other (incl. re-infection)</cell><cell>3.1</cell><cell>3.2</cell><cell>3.1</cell><cell></cell></row><row><cell>Route of transmission, %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Drug abuse</cell><cell>19.4</cell><cell>19.0</cell><cell>20.6</cell><cell>n.s.</cell></row><row><cell>Blood products</cell><cell>17.4</cell><cell>17.7</cell><cell>16.6</cell><cell></cell></row><row><cell>Medical/surgical intervention</cell><cell>8.5</cell><cell>7.9</cell><cell>10.0</cell><cell></cell></row><row><cell>Sexual contact</cell><cell>1.7</cell><cell>1.3</cell><cell>2.7</cell><cell></cell></row><row><cell>other</cell><cell>3.4</cell><cell>3.3</cell><cell>3.8</cell><cell></cell></row><row><cell>unknown</cell><cell>49.7</cell><cell>50.8</cell><cell>46.3</cell><cell></cell></row><row><cell>Frequent comorbidities, %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cardiovascular disease</cell><cell>20.5</cell><cell>21.0</cell><cell>19.1</cell><cell>n.s.</cell></row><row><cell>Psychiatric disorder</cell><cell>12.4</cell><cell>11.8</cell><cell>14.2</cell><cell>n.s.</cell></row><row><cell>Thyroidal dysfunction</cell><cell>9.1</cell><cell>9.3</cell><cell>8.4</cell><cell>n.s.</cell></row><row><cell>Diabetes mellitus</cell><cell>7.8</cell><cell>8.1</cell><cell>6.9</cell><cell>n.s.</cell></row><row><cell>History of drug/alcohol abuse</cell><cell>18.4</cell><cell>17.5</cell><cell>20.8</cell><cell>n.s.</cell></row><row><cell>HBV-coinfection</cell><cell>0.8</cell><cell>0.7</cell><cell>1.1</cell><cell>n.s.</cell></row><row><cell>Baseline viral load, IU/ml</cell><cell>3,0 x 10 6</cell><cell>3,0 x 10 6</cell><cell>3,1 x 10 6</cell><cell>n.s.</cell></row><row><cell>Baseline viral load, % (n = 1,742)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>400,000 IU/ml</cell><cell>27.2</cell><cell>26.7</cell><cell>28.6</cell><cell>n.s.</cell></row><row><cell>&gt; 400,000 IU/ml</cell><cell>72.8</cell><cell>73.3</cell><cell>71.4</cell><cell></cell></row><row><cell>AST, U/l</cell><cell>67.7</cell><cell>69.4</cell><cell>62.8</cell><cell>0.0106</cell></row><row><cell>ALT, U/l</cell><cell>92.7</cell><cell>95.5</cell><cell>84.5</cell><cell>n.s.</cell></row><row><cell>APRI-score at baseline (n = 1,483)</cell><cell>1.0</cell><cell>1.1</cell><cell>0.9</cell><cell>0.0122</cell></row><row><cell>APRI-score at baseline categorized, % (n = 1,483)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0.5</cell><cell>42.9</cell><cell>42.3</cell><cell>44.8</cell><cell>n.s.</cell></row><row><cell>&gt; 0.5 and 1.5</cell><cell>39.8</cell><cell>39.2</cell><cell>41.5</cell><cell></cell></row><row><cell>&gt; 1.5</cell><cell>17.3</cell><cell>18.5</cell><cell>13.7</cell><cell></cell></row><row><cell>doi:10.1371/journal.pone.0159976.t001</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Treatment outcomes by patient group.</s></p></div></figDesc><table><row><cell>Treatment outcome</cell></row></table><note><p><s>No SVR, % (Patients with treatment discontinuation due to nonresponse or AEs or personal reasons and patients with relapse) Lost to follow-up, not tested, %</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Treatment costs by patient group.</s></p></div></figDesc><table><row><cell>Costs, €</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Costs per SVR for patient groups.</s></p></div></figDesc><table><row><cell>Patient group</cell><cell>n</cell><cell>SVR, %</cell><cell>Treatment costs, €</cell><cell>Costs per SVR, €</cell></row><row><cell>Treatment-naive</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TVR</cell><cell>548</cell><cell>62.2</cell><cell>50,598</cell><cell>81,347</cell></row><row><cell>BOC</cell><cell>246</cell><cell>55.7</cell><cell>39,081</cell><cell>70,163</cell></row><row><cell>Treatment-experienced</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prior Relapser</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TVR</cell><cell>429</cell><cell>68.5</cell><cell>53,491</cell><cell>78,089</cell></row><row><cell>BOC</cell><cell>103</cell><cell>63.5</cell><cell>52,119</cell><cell>82,077</cell></row><row><cell>Prior Non-Responder</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TVR</cell><cell>316</cell><cell>45.6</cell><cell>53,128</cell><cell>116,509</cell></row><row><cell>BOC</cell><cell>87</cell><cell>39.1</cell><cell>43,071</cell><cell>110,156</cell></row></table><note><p><s>doi:10.1371/journal.pone.0159976.t004</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Quality of life at baseline.</s></p></div></figDesc><table><row><cell>HCV-patients</cell><cell>German norm population</cell></row></table><note><p><s>Fig 1. QoL development during treatment.</s><s>doi:10.1371/journal.pone.0159976.g001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 6 .</head><label>6</label><figDesc><div><p><s>Post treatment QoL-SVR vs. no SVR.</s></p></div></figDesc><table><row><cell>No SVR (n = 106)</cell><cell>SVR (n = 378)</cell><cell>No SVR vs. SVR</cell><cell>Total (n = 484)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | DOI:10.1371/journal.pone.0159976July 28, 2016  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Competing Interests: JTS: research funding by Gilead, AbbVie, Janssen-Cilag; Travel support/lecture fees by Roche and Janssen-Cilag.</s><s>SR: study funding from Gilead and Janssen, advisory board member for MSD.</s><s>FB: no conflict of interest.</s><s>KHWB: received fees for serving as a speaker for Janssen, Gilead, BMS, AbbVie, Roche and Merck/MSD.</s><s>HRB: no conflict of interest.</s><s>CE: speaker fees from AbbVie, Gilead Sciences, Janssen, Roche, MSD.</s><s>RL: no conflict of interest.</s><s>CJ: no conflict of interest.</s><s>SM: Board membership and consultancy for AbbVie, BMS, Boehringer Ingelheim, Gilead, Janssen, Roche; Payment for lectures including service on speakers bureaus from AbbVie, BMS, Gilead, Janssen, MSD, Roche; Travel/accommodations/meeting expenses from AbbVie, BMS, Gilead.</s><s>RH: has served as a speaker, consultant and advisory board member for Gilead, AbbVie, MSD, Intercept, BMS, Bayer, Alexion.</s><s>ES: fees for serving as speaker, consultant and advisory board member for AbbVie, BMS, Gilead, Johnson &amp; Johnson and MSD.</s><s>HPV: employee of e-factum -GmbH, a contract research organisation.</s><s>DH: lecture fees, consulting fees and/or research funding from MSD Sharp&amp;Dohme.</s><s>GmbH, Janssen-Cilag GmbH, Roche Pharma AG, Bristol-Myers Squibb GmbH&amp;Co.KGaA, Falk Pharma, Boehringer Ingelheim Pharma GmbH &amp; Co.KG, Novartis Pharma Germany GmbH, Norgine GmbH, Shire Deutschland GmbH, Abbott/AbbVie GmbH &amp; Co.KG, Gilead Sciences GmbH, Ferring Arzneimittel GmbH, Merckle Recordati GmbH, Merz Pharmaceuticals GmbH, Echosens S.A.S.U.</s><s>CK: research funding by Gilead, AbbVie, Janssen-Cilag.</s><s>This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection</title>
		<imprint>
			<date type="published" when="2014">2014</date>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination</title>
		<author>
			<persName><forename type="first">C</forename><surname>Poethko-Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamouda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Ross</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Survey for Adults (DEGS1)</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<idno type="DOI">10.1007/s00103-013-1673-x</idno>
		<idno type="PMID">23703489</idno>
	</analytic>
	<monogr>
		<title level="j">Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">5-6</biblScope>
			<biblScope unit="page" from="707" to="715" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vermehren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schlosser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Domke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Elanjimattom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hintereder</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0041206</idno>
		<idno type="PMID">22848445</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e41206</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Historical epidemiology of hepatitis C virus (HCV) in selected countries</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bruggmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Ovrehus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brandao</forename><surname>Mello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Roudot-Thoraval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<idno type="DOI">10.1111/jvh.12247</idno>
		<idno type="PMID">24713004</idno>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="5" to="33" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Epidemiology of chronic hepatitis C in Germany-an analysis of 10</title>
		<author>
			<persName><forename type="first">D</forename><surname>Huppe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Zehnter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Racky</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>326 patients in hepatitis centres and outpatient units</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<idno type="DOI">10.1055/s-2007-963691</idno>
		<idno type="PMID">18188814</idno>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="34" to="44" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">New hepatitis C therapies: the toolbox, strategies, and challenges</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pawlotsky</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2014.03.003</idno>
		<idno type="PMID">24631495</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1176" to="1192" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Perz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Farrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Hutin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Bell</surname></persName>
		</author>
		<idno type="PMID">16879891</idno>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="529" to="538" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Challenges to liver transplantation and strategies to improve outcomes</title>
		<author>
			<persName><forename type="first">P</forename><surname>Dutkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Linecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Deoliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mullhaupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Clavien</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.gastro.2014.08.045</idno>
		<idno type="PMID">25224524</idno>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="307" to="323" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Innes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Allen</forename><forename type="middle">S</forename><surname>Hayes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<idno type="DOI">10.1002/hep.27766</idno>
		<idno type="PMID">25716707</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="355" to="364" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Der Meer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Veldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Feld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lammert</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2012.144878</idno>
		<idno type="PMID">23268517</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">308</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2584" to="2593" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sarkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Evon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Wahed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hoofnagle</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2012.06.030</idno>
		<idno type="PMID">22760009</idno>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="946" to="952" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<author>
			<persName><forename type="first">Bundesausschuss</forename><surname>Gemeinsamen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII-Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach §35a des Fünften Buches Sozialgesetzbuch (SGB V) Boceprevir</title>
				<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page">1269</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<author>
			<persName><forename type="first">Bundesausschuss</forename><surname>Gemeinsamer</surname></persName>
		</author>
		<title level="m">Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII-Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Telaprevir. Bundesanzeiger</title>
				<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Antiviral treatment of hepatitis C</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Feeney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page">3308</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting</title>
		<author>
			<persName><forename type="first">B</forename><surname>Maasoumy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Port</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Markova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Serrano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rogalska-Taranta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sollik</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0055285</idno>
		<idno type="PMID">23383319</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e55285</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Costs of telaprevirbased triple therapy for hepatitis C: $189,000 per sustained virological response</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bichoupan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Martel-Laferriere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sachs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Schonfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pappas</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.27340</idno>
		<idno type="PMID">25065814</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1187" to="1195" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Vo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vutien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Akiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Vu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Piotrowski</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10620-015-3621-0</idno>
		<idno type="PMID">25821099</idno>
	</analytic>
	<monogr>
		<title level="j">Dig Dis Sci</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1045" to="1051" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Buggisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schott</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-0034-1399383</idno>
		<idno type="PMID">26167694</idno>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="644" to="654" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Costs and outcomes of treating chronic hepatitis C patients in routine care-results from a nationwide multicenter trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Stahmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Krauth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pfeiffer-Vornkahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Alshuth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huppe</surname></persName>
		</author>
		<idno type="DOI">10.1111/jvh.12471</idno>
		<idno type="PMID">26411532</idno>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="105" to="115" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moog</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0134839</idno>
		<idno type="PMID">26230998</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e0134839</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Buggisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Schott</surname></persName>
		</author>
		<idno type="DOI">10.1055/s-0034-1399383</idno>
		<idno type="PMID">26167694</idno>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="644" to="654" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title level="m" type="main">Einheitlicher Bewertungsmaßstab (EBM)</title>
		<author>
			<persName><forename type="first">Bundesvereinigung</forename><surname>Kassenärztliche</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<monogr>
		<title level="m" type="main">Rote Liste 1 Service GmbH. ROTE LISTE 1 -Online</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Telaprevir for previously untreated chronic hepatitis C virus infection</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Mchutchison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dusheiko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Bisceglie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Bzowej</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1012912</idno>
		<idno type="PMID">21696307</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2405" to="2416" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Boceprevir for untreated chronic HCV genotype 1 infection</title>
		<author>
			<persName><forename type="first">F</forename><surname>Poordad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mccone</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Bacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Manns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Sulkowski</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1010494</idno>
		<idno type="PMID">21449783</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1195" to="1206" />
			<date type="published" when="2011">2011. NEJMoa1010494</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Boceprevir for previously treated chronic HCV genotype 1 infection</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Bacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Marcellin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Vierling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1009482</idno>
		<idno type="PMID">21449784</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1207" to="1217" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Telaprevir for retreatment of HCV infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Andreone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roberts</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1013086</idno>
		<idno type="PMID">21696308</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2417" to="2428" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Backus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Belperio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Shahoumian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Mole</surname></persName>
		</author>
		<idno type="DOI">10.1111/apt.12546</idno>
		<idno type="PMID">24206566</idno>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="93" to="103" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Safety and efficacy of protease inhibitor based combination therapy in a single-center &quot;real-life&quot; cohort of 110 patients with chronic hepatitis C genotype 1 infection</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Wehmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Eissing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jordan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hennigs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Degen</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-230X-14-87</idno>
		<idno type="PMID">24884400</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C</title>
		<author>
			<persName><forename type="first">C</forename><surname>Camma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Petta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Enea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bronte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Capursi</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.25734</idno>
		<idno type="PMID">22454336</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="850" to="860" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C</title>
		<author>
			<persName><forename type="first">C</forename><surname>Camma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Petta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cabibbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruggeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Enea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruno</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2013.05.019</idno>
		<idno type="PMID">23707373</idno>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="658" to="666" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chhatwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Ferrante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Brass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Burroughs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bacon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2013.07.006</idno>
		<idno type="PMID">24041347</idno>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="973" to="986" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bianic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gavart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dusheiko</surname></persName>
		</author>
		<idno type="DOI">10.3111/13696998.2013.860033</idno>
		<idno type="PMID">24160335</idno>
	</analytic>
	<monogr>
		<title level="j">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="65" to="76" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bianic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gavart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dusheiko</surname></persName>
		</author>
		<idno type="DOI">10.3111/13696998.2013.844159</idno>
		<idno type="PMID">24032626</idno>
	</analytic>
	<monogr>
		<title level="j">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="77" to="87" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Cipriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holodniy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Goldhaber-Fiebert</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-156-4-201202210-00005</idno>
		<idno type="PMID">22351713</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="279" to="290" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Stahmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rossol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bianic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of Health Economics and Outcomes Research</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="239" to="253" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ferenci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lalezari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cooper</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1402338</idno>
		<idno type="PMID">24795200</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="1983" to="1992" />
			<date type="published" when="2014">2014. NEJMoa1402338</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</title>
		<author>
			<persName><forename type="first">N</forename><surname>Afdhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kwo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chojkier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gitlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Puoti</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1402454</idno>
		<idno type="PMID">24725239</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1889" to="1898" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rossaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lawitz</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1402355</idno>
		<idno type="PMID">24720702</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1879" to="1888" />
			<date type="published" when="2014">2014. NEJMoa1402355</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Feld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Coakley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sigal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Crawford</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1315722</idno>
		<idno type="PMID">24720703</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1594" to="1603" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Poordad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hezode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Trinh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zeuzem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Agarwal</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1402869</idno>
		<idno type="PMID">24725237</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="1973" to="1982" />
			<date type="published" when="2014">2014. NEJMoa1402869</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Recommendations on Treatment of Hepatitis C 2015</title>
		<author>
			<persName><surname>Easl</surname></persName>
		</author>
		<author>
			<persName><surname>Easl</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2015.03.025</idno>
		<idno type="PMID">25911336</idno>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="199" to="236" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus</title>
		<author>
			<persName><forename type="first">Aasld</forename><surname>Hepatitis C Guidance</surname></persName>
		</author>
		<idno type="DOI">10.1002/hep.27950</idno>
		<idno type="PMID">26111063</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="932" to="954" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Therapy for hepatitis C-the costs of success</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hoofnagle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Sherker</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMe1401508</idno>
		<idno type="PMID">24725236</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1552" to="1553" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Advocates protest the cost of a hepatitis C cure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.342.6164.1302</idno>
		<idno type="PMID">24337268</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="issue">6164</biblScope>
			<biblScope unit="page" from="1302" to="1303" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Pharmaceuticals</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Stahmeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rossol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Krauth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comp Eff Res</title>
		<imprint>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title level="m" type="main">Hepatitis C drug delayed by NHS due to high cost. The Guardian</title>
		<author>
			<persName><forename type="first">S</forename><surname>Boseley</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page" from="16" to="17" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title level="m" type="main">Hépatite C: le nouveau hold-up des labos</title>
		<author>
			<persName><forename type="first">P</forename><surname>Santi</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014-07-08">Le Monde 8-7-2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">Hepatitis C patients stage sit-in to demand access to new treatment</title>
		<imprint>
			<date type="published" when="2014-12-19">El Pais 19-12-2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of novel regimens for the treatment of hepatitis C virus</title>
		<author>
			<persName><forename type="first">M</forename><surname>Najafzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Shrank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Krumme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">S</forename><surname>Matlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brennan</surname></persName>
		</author>
		<idno type="DOI">10.7326/M14-1152</idno>
		<idno type="PMID">25775313</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="407" to="419" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Younossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dieterich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<idno type="DOI">10.1111/apt.13081</idno>
		<idno type="PMID">25619871</idno>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="544" to="563" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Bastian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Griffin</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12876-015-0320-4</idno>
		<idno type="PMID">26239358</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">98</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chhatwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kanwal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dunn</surname></persName>
		</author>
		<idno type="DOI">10.7326/M14-1336</idno>
		<idno type="PMID">25775312</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="397" to="406" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report</title>
		<author>
			<persName><forename type="first">M</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Barbieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Glick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Malik</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1524-4733.2008.00489.x</idno>
		<idno type="PMID">19900249</idno>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="409" to="418" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
